Jefferies Financial Group Raises Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 2,025

Hikma Pharmaceuticals (LON:HIK) had its target price boosted by research analysts at Jefferies Financial Group from GBX 1,870 to GBX 2,025 in a research report issued on Tuesday,London Stock Exchange reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside of 24.00% from the company’s previous close.

A number of other analysts also recently weighed in on HIK. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

Shares of LON:HIK opened at GBX 1,633 on Tuesday. Hikma Pharmaceuticals has a 12-month low of GBX 1,187 and a 12-month high of GBX 1,865. The stock has a market cap of £3.41 billion, a PE ratio of 9.02, a P/E/G ratio of 2.38 and a beta of 0.66. The business has a 50 day moving average of GBX 1,574.60 and a 200-day moving average of GBX 1,460.22. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.04% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.